FTHFX
Price
$58.72
Change
+$0.60 (+1.03%)
Updated
Sep 11 closing price
Net Assets
12.15B
VSMSX
Price
$530.54
Change
+$2.93 (+0.56%)
Updated
Sep 11 closing price
Net Assets
6.45B
Interact to see
Advertisement

FTHFX vs VSMSX

FTHFX vs VSMSX Comparison Chart in %
View a ticker or compare two or three
VS
FTHFX vs. VSMSX commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FTHFX is a Buy and VSMSX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FTHFX has more cash in the bank: 12.1B vs. VSMSX (6.45B). VSMSX pays higher dividends than FTHFX: VSMSX (1.15) vs FTHFX (0.56). FTHFX was incepted earlier than VSMSX: FTHFX (15 years) vs VSMSX (15 years). FTHFX (0.64) is less costly to investors than VSMSX (0.03). FTHFX is a more actively managed with annual turnover of: 28.00 vs. VSMSX (22.00). FTHFX has a lower initial minimum investment than VSMSX: FTHFX (1000000) vs VSMSX (5000000). VSMSX annual gain was more profitable for investors over the last year : 18.18 vs. FTHFX (15.30). FTHFX return over 5 years is better than : 60.92 vs. VSMSX (32.65).
FTHFXVSMSXFTHFX / VSMSX
Total Expense Ratio0.640.032,133%
Annual Report Gross Expense Ratio0.640.032,133%
Fund Existence15 years15 years-
Gain YTD14.83918.22181%
Front LoadN/AN/A-
Min. Initial Investment1000000500000020%
Min. Initial Investment IRAN/AN/A-
Net Assets12.1B6.45B188%
Annual Yield % from dividends0.561.1549%
Returns for 1 year15.3018.1884%
Returns for 3 years58.6847.19124%
Returns for 5 years60.9232.65187%
Returns for 10 years237.29145.99163%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LKQ24.110.48
+2.03%
LKQ Corp
NKSH42.840.36
+0.85%
National Bankshares
PBR21.20-0.18
-0.84%
Petroleo Brasileiro Sa-Petrobras ADS (REP 1 Common Share)
TYRA22.03-1.51
-6.41%
Tyra Biosciences
ACTU1.07-0.08
-6.96%
Actuate Therapeutics Inc